Clinical characteristics and the long-term outcome of patients with atypical POEMS syndrome variant with undetectable monoclonal gammopathy.

Abstract

The diagnosis of polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome requires polyneuropathy and monoclonal plasma cell proliferation as two mandatory criteria. Our aim was to summarize clinical manifestations and treatment responses of POEMS variants with no evidence of monoclonal gammopathy. We queried all medical documentation of patients referred to Peking Union Medical College Hospital from August 2012 to July 2017, and reviewed the clinical and laboratory features of 13 patients with atypical POEMS syndrome with undetectable monoclonal gammopathy, and compared to prototypes published. The prevalence of polyneuropathy, organomegaly, skin changes, and extravascular fluid overload were 100%, 100%, 92%, and 100%, respectively. Other clinical manifestations, such as endocrinopathy, pulmonary hypertension, papilledema, thrombocytosis, and polycythemia affected similar percentages of patients as seen in prototypes. POEMS variants enrolled had a median serum vascular endothelial growth factor (VEGF) level of 4998 pg/ml (range 2155-11,029 pg/ml). Long-term follow-up found that all 12 patients received autologous stem cell transplant, melphalan-based therapy or lenalidomide/thalidomide-based therapy obtained clinical improvement, of which eight experienced decreased levels of VEGF by 50% or back to normal. The median progression-free survival was 101.5 months. Our findings raised a variant of POEMS syndrome variants with featured clinical manifestations, elevated VEGF levels, and good response to therapies targeting plasma cell.

• Authors: Tianhua He, Ailin Zhao, Hao Zhao, Hao Cai, Jun Feng, Lu Zhang, Xinxin Cao, Daobin Zhou, Jian Li
• Journal: Annals of hematology (Ann Hematol) Vol. 98 Issue 3 Pg. 735-743 (Mar 2019) ISSN: 1432-0584 [Electronic] Germany
• PMID: 30612232 (Publication Type: Journal Article)

Chemical References

• VEGFA protein, human
• Vascular Endothelial Growth Factor A

Topics

• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Combined Modality Therapy
• Female
• Hematopoietic Stem Cell Transplantation
• Humans
• Male
• Middle Aged
• Monoclonal Gammopathy of Undetermined Significance (blood, drug therapy, epidemiology, therapy)
• POEMS Syndrome (blood, drug therapy, epidemiology, therapy)
• Phenotype
• Progression-Free Survival
• Symptom Assessment
• Transplantation, Autologous
• Treatment Outcome
• Vascular Endothelial Growth Factor A (blood)